Azacitidine interactions
Full monograph for AzacitidineCheck it against another medicine
Medicines
42 documented
Mechanism
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Adalimumab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Baricitinib | Major | Synergy | Coadministration of baricitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies… | 4 sources — open the full entry |
| Clozapine | Major | Synergy | Coadministration of clozapine with other agents that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity. | 9 sources — open the full entry |
| Deferiprone | Major | Synergy | Coadministration of deferiprone and other drugs that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity… | 5 sources — open the full entry |
| Etanercept | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Golimumab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Infliximab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Leflunomide | Major | Synergy | The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to… | 2 sources — open the full entry |
| Rotavirus Vaccine | Major | Others | The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of… | 9 sources — open the full entry |
| Thalidomide | Major | Synergy | Coadministration of thalidomide with glucocorticoids and/or antineoplastic agents in the treatment of malignancy may potentiate the risk of thromboembolism… | 20 sources — open the full entry |
| Tofacitinib | Major | Others | Coadministration of tofacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies… | 1 sources — open the full entry |
| Upadacitinib | Major | Others | Coadministration of upadacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. | 1 sources — open the full entry |
| Yellow Fever Vaccine | Major | Others | The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of…2 documented mechanisms | 19 sources — open the full entry |
| Azathioprine | Moderate | Synergy | The use of azathioprine with other immunosuppressive or myelosuppressive agents may result in additive hematologic toxicities and increased risk of infections… | 3 sources — open the full entry |
| Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocaine | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of… | 8 sources — open the full entry |
| Beta carotene + Vitamin C + Vitamin E | Moderate | Others | The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses… | 9 sources — open the full entry |
| Chloramphenicol (Ophthalmic) | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of… | 8 sources — open the full entry |
| Chloramphenicol (Oral) | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of… | 8 sources — open the full entry |
| Chloramphenicol + Lidocaine Hydrochloride | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of… | 8 sources — open the full entry |
| Denosumab | Moderate | Synergy | Concomitant use of immunosuppressive or myelosuppressive agents with denosumab may increase the risk of serious infections. Denosumab binds to and inhibits the… | 2 sources — open the full entry |
| Dexamethasone + Chloramphenicol | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of… | 8 sources — open the full entry |
| Diphtheria + Tetanus + Pertussis + Hepatitis B + Polio + HIB | Moderate | Antagonism | The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a… | 10 sources — open the full entry |
| Diroximel Fumarate | Moderate | Synergy | The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may… | 1 sources — open the full entry |
| Filgrastim | Moderate | Antagonism | INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given… | 4 sources — open the full entry |
| Ganciclovir | Moderate | Synergy | The use of ganciclovir with other potentially myelotoxic and/or nephrotoxic agents may increase the risk and severity of hematologic toxicity and/or… | 7 sources — open the full entry |
| Hepatitis B Vaccine [rDNA] | Moderate | Antagonism | The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a… | 10 sources — open the full entry |
| Inactivated Hepatitis A vaccine | Moderate | Antagonism | The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a… | 10 sources — open the full entry |
| Lactobacillus Rhamnosus GG | Moderate | Others | Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms… | 11 sources — open the full entry |
| Lamivudine + Zidovudine | Moderate | Synergy | Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity… | 8 sources — open the full entry |
| Lamivudine + Zidovudine + Nevirapine | Moderate | Synergy | Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity… | 8 sources — open the full entry |
| Lenograstim | Moderate | Antagonism | INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given… | 4 sources — open the full entry |
| Niraparib | Moderate | Synergy | Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with niraparib. Myelodysplastic syndrome… | 1 sources — open the full entry |
| Ocrelizumab | Moderate | Synergy | The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of… | 1 sources — open the full entry |
| Olaparib | Moderate | Synergy | Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with olaparib. Myelodysplastic syndrome… | 4 sources — open the full entry |
| Pegfilgrastim [Pegylated Filgrastim] | Moderate | Antagonism | INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given… | 2 sources — open the full entry |
| Roflumilast (Tablet) | Moderate | Synergy | The concomitant use of roflumilast with immunosuppressive agents has not been adequately studied. Specifically, roflumilast and its active metabolite… | 5 sources — open the full entry |
| Tea Tree Oil + Geothermal Water + Vitamin E | Moderate | Others | The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses… | 9 sources — open the full entry |
| Topotecan | Moderate | Synergy | The use of topotecan with other cytotoxic agents is likely to result in greater myelosuppression due to additive or synergistic pharmacologic effects. Severe… | 1 sources — open the full entry |
| Typhoid conjugate vaccine | Moderate | Antagonism | The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a… | 10 sources — open the full entry |
| Typhoid polysaccharide vaccine | Moderate | Others | The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a… | 11 sources — open the full entry |
| Vitamin C + Vitamin E | Moderate | Others | The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses… | 9 sources — open the full entry |
| Vitamin C + Vitamin E + Lutein + Copper + Zinc | Moderate | Others | The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses… | 9 sources — open the full entry |
Conditions
Conditions in which Azacitidine needs care, as documented in this source.
Liver Neoplasms
MajorThe use of azacitidine injection is contraindicated in patients with advanced malignant hepatic tumors.
1 source
- "Product Information. Vidaza (azacitidine)." Celgene Corporation (2004):
Anemia
ModerateSome miscellaneous antineoplastics such as azacitidine and lenalidomide cause anemia, neutropenia, and thrombocytopenia. Patients with these preexisting conditions should be monitored carefully. Monitor complete blood counts frequently for response and/or toxicity, at a minimum, prior to each dosing cycle.
2 sources
- "Product Information. Vidaza (azacitidine)." Celgene Corporation (2004):
- "Product Information. Revlimid (lenalidomide)." Celgene Corporation (2006):
Hepatic Insufficiency
ModerateAzacitidine is potentially hepatotoxic in patients with preexisting hepatic impairment and caution should be exercised when prescribing in patients with liver disease.
1 source
- "Product Information. Vidaza (azacitidine)." Celgene Corporation (2004):
Kidney Diseases
ModeratePatients with renal impairment may be at increased risk of renal toxicity when using azacitidine. This drug is primarily excreted by the kidneys. Therefore, these patients should be closely monitored for toxicity.
1 source
- "Product Information. Vidaza (azacitidine)." Celgene Corporation (2004):
Therapeutic duplication
Drug classes that overlap with Azacitidine, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
dna methyltransferase inhibitors
The recommended maximum number of medicines in the 'DNA methyltransferase inhibitors' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'DNA methyltransferase inhibitors' category.
Example product in the source data (US market): Inqovi